Alamar Biosciences

US · ALMR #2657 by market cap Listed 2026

27.77 -4.49 -13.92%

Live - 5344 symbols - heartbeat 31s ago · 2026-10-08 07:00

Pre-market 28.06 +1.04%

After-hours 28.50 +2.63%

Overnight 27.90 +0.47%

Market cap: 1.93B
P/E (TTM): -38.78
P/B: 6.16
EPS: -0.54
Div yield: 0.00%
52W pos: 43%

Reader sentiment Are you bullish or bearish on ALMR?

Anonymous reader poll. Unscientific, not investment advice.

About Alamar Biosciences

Alamar Biosciences, Inc. engages in developing a proteomic liquid biopsy platform and sells instruments, consumables & services for the early detection of diseases. Its products include ARGO HT system, NULISA assays for Immunology, neurology & oncology, NULISAqpcr custom assay development, technology access program and Alamar analysis solutions. The company was founded by Yuling Luo, Yiyuan Yin and Steve Chen in May 2018 and is headquartered in Fremont, CA.

Founded: 2018
CEO: Dr. Yuling Luo, PhD
Employees: 222
Headquarters: Fremont, California, United States of America
Fiscal year end: 12-31
Website: alamarbio.com

Company profile

Exchange: US
Symbol: ALMR
Market-cap rank: #2657
Listing date: 2026-04-17
Market cap: 1.93B
Float cap: 359.27M
Shares out: 69.39M
Float shares: 12.94M

Sectors & themes

Medical Devices IPOs

Browse all sectors & themes

Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.